Risk Evaluation and Stratification of Low Risk for Cardiovascular Disease in Women (RESOLVE)

April 26, 2019 updated by: Elsie Nguyen

Risk Evaluation and Stratification of Low Risk for Cardiovascular Disease in Women: An Innovative Strategy for Investigating Stable Chest Pain in Low to Intermediate Risk Women

This study will evaluate the ability of Coronary Computed Tomography Angiography (CCTA), used as a first-line diagnostic tool in women with stable chest pain and low risk for Coronary Artery Disease (CAD), to reduce the number of women requiring more than one diagnostic test to rule in or rule out CAD. Half of the participants will undergo CCTA as the first test to investigate stable chest pain, while the other half will undergo any test ordered by their family physician.

Study Overview

Detailed Description

Coronary artery disease (CAD) is the leading cause of death in women globally. Women are more likely to present with atypical chest pain that may be difficult to diagnose using traditional testing methods, resulting in over-investigation.

Coronary computed tomography angiography (CCTA) has high negative predictive value for exclusion of CAD in low to intermediate risk populations. We plan to investigate CCTA as a first line test to exclude coronary artery disease as a cause of stable chest pain and whether it is a cost effective strategy that reduces time to diagnosis, wait times to see cardiologists, emergency department visits, downstream and repeat testing and radiation exposure as compared to usual care with comparable patient safety and satisfaction level.

Another intervention being tested in this trial is the Cardiac Link pathway. This is a new clinical program at Women's College Hospital that aims to expedite cardiology referral for patients exhibiting clinically significant findings while undergoing CCTAs.

We hope that with use of CCTA as the first test, the number of women who require only one test (i.e. CCTA) to sort out whether or not CAD is responsible for their chest pain will increase, thereby decreasing over-investigation of low risk women.

Study Type

Interventional

Enrollment (Anticipated)

130

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5S1B2
        • Recruiting
        • Women's College Hospital
        • Principal Investigator:
          • Paula J Harvey, BMBS
        • Sub-Investigator:
          • Deborah Levitan, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women age ≥ 40 years of age
  • Stable chest pain or equivalent symptoms
  • Planned non-urgent, non-invasive testing for diagnosis of chest pain or equivalent symptoms

Exclusion Criteria:

  • Acute coronary syndrome, including acute myocardial infarction or unstable angina, known non-ischemic cardiomyopathy or other cardiac disease (e.g. mitral valve prolapse, etc.) which would require urgent cardiac evaluation
  • Known CAD
  • Prior cardiac evaluation for current episode of symptoms
  • Previously investigated for CAD in the last 12 months
  • Severe allergic reaction to iodinated contrast (mild reactions such as urticaria that can be controlled by premedication with Benadryl & Prednisone may be included in the study)
  • Renal failure or dysfunction (estimated Glomerular Filtration Rate<30ml/min/m2 within the past 3 months)
  • Pregnancy (status will be confirmed verbally. For premenopausal patients who are unsure, status will be confirmed by completing a pregnancy strip test).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: DIAGNOSTIC
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: CCTA first approach with Cardiac Link
Patient will undergo Coronary Computed Tomography Angiography as the first test and have Cardiac Link pathway activated for expedited cardiology referral.
Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.
Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.
EXPERIMENTAL: CCTA first approach without Cardiac Link
Patient will undergo Coronary Computed Tomography Angiography as the first test, but Cardiac Link pathway will not be activated.
Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.
ACTIVE_COMPARATOR: Usual Care with Cardiac Link
Patient will undergo the usual diagnostic test ordered by their family physician as the first test, and have Cardiac Link pathway activated for expedited cardiology referral.
Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.
Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.
ACTIVE_COMPARATOR: Usual Care without Cardiac Link
Patient will undergo the usual diagnostic test ordered by their family physician as the first test, but Cardiac Link pathway will not be activated.
Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total Number of Tests
Time Frame: Through study completion, which may take up to 1 year
The total number of tests a patient has to complete in order to diagnose the cause of their chest pain or equivalent symptoms
Through study completion, which may take up to 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Diagnosis
Time Frame: From date of first presentation with chest pain to date of CAD diagnosis or exclusion, assessed up to 24 months
Time interval from time of presentation to family physician for evaluation of chest pain to the last test performed to determine etiology of chest pain or CAD exclusion.
From date of first presentation with chest pain to date of CAD diagnosis or exclusion, assessed up to 24 months
Wait Times to See a Cardiologist
Time Frame: From date of cardiology referral letter sent by family physician to date of cardiologist appointment with patient, assessed up to 24 months
Time interval from when family physician referral letter was sent to the cardiologist's office to appointment time to see cardiologist
From date of cardiology referral letter sent by family physician to date of cardiologist appointment with patient, assessed up to 24 months
Hospital/ER visits
Time Frame: Through study completion, which may take up to 1 year
Number of hospital/ER visits while waiting to see cardiologist
Through study completion, which may take up to 1 year
Number of Normal Invasive Diagnostic Angiograms
Time Frame: From date of randomization to date of CAD diagnosis or exclusion, assessed up to 24 months
Number of invasive diagnostic angiograms done that reveal no coronary artery disease.
From date of randomization to date of CAD diagnosis or exclusion, assessed up to 24 months
Total Cost of Investigations
Time Frame: Through study completion, which may take up to 1 year
Total cost (in Canadian dollars) of all tests completed to reach a diagnosis for chest pain
Through study completion, which may take up to 1 year
Cumulative Radiation Dose Exposure (milliSieverts)
Time Frame: From date of randomization to date of CAD diagnosis or exclusion, assessed up to 24 months
Total effective radiation dose from all testing modalities for each patient.
From date of randomization to date of CAD diagnosis or exclusion, assessed up to 24 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Procedure Related Adverse Events
Time Frame: From date of randomization to date of CAD diagnosis or exclusion, assessed up to 24 months
Assessment of diagnostic procedure related adverse effects that may occur during the course of the trial.
From date of randomization to date of CAD diagnosis or exclusion, assessed up to 24 months
Incidence of Cardiovascular Events
Time Frame: From date of randomization to date of CAD diagnosis or exclusion, assessed up to 24 months
Assessment of cardiovascular events that may take place during the course of the study, while waiting for a diagnosis for the cause of chest pain
From date of randomization to date of CAD diagnosis or exclusion, assessed up to 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Elsie T Nguyen, MD, FRCPC, Women's College Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 24, 2019

Primary Completion (ANTICIPATED)

January 1, 2021

Study Completion (ANTICIPATED)

January 1, 2021

Study Registration Dates

First Submitted

January 15, 2019

First Submitted That Met QC Criteria

April 23, 2019

First Posted (ACTUAL)

April 26, 2019

Study Record Updates

Last Update Posted (ACTUAL)

April 30, 2019

Last Update Submitted That Met QC Criteria

April 26, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2014-0069-B

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chest Pain

Clinical Trials on Coronary Computed Tomography Angiography (CCTA)

Subscribe